Circulation Journal, Год журнала: 2024, Номер 88(11), С. 1770 - 1777
Опубликована: Июнь 19, 2024
Because apolipoprotein-A2 (ApoA2), a key component of high-density lipoprotein cholesterol (HDL-C), lacks clear clinical significance, we investigated its impact on cardiovascular events in patients undergoing percutaneous coronary intervention (PCI).
Язык: Английский
Journal of Atherosclerosis and Thrombosis, Год журнала: 2016, Номер 24(1), С. 19 - 25
Опубликована: Окт. 11, 2016
Statin treatment to reduce low-density lipoprotein cholesterol (LDL-C) is associated with the prevention of cardiovascular events in Western patients. Similar results have been reported studies conducted Japan. However, dose statins and degree LDL-C reduction achieved are different between Asian In addition, there limited data regarding racial differences response statins. this review, Asians Westerners described.
Язык: Английский
Процитировано
107
BMJ Open, Год журнала: 2016, Номер 6(2), С. e010080 - e010080
Опубликована: Фев. 1, 2016
Objective Japan's 2011 Fukushima Daiichi Nuclear Power Plant incident required the evacuation of over a million people, creating large displaced population with potentially increased vulnerability in terms chronic health conditions. We assessed long-term impact on diabetes, hyperlipidaemia and hypertension. Participants considered participants annual public check-ups from 2008 to 2014, administrated by Minamisoma City Soma City, located about 10–50 km nuclear plant. Methods Disease risks, measured pre-incident post-incident relative were examined compared between evacuees non-evacuees/temporary-evacuees. also constructed logistic regression models assess disease risks adjusted for covariates. Results Data total 6406 individuals aged 40–74 years who participated both at baseline (2008–2010) one or more analysed. Regardless evacuation, significant increases risk observed diabetes (relative risk: 1.27–1.60 1.12–1.30, respectively, depending status year). After adjustment covariates, increase was significantly greater among than non-evacuees/temporary-evacuees (OR 1.18, 95% CI 1.06 1.32, p<0.01). Conclusions The singularity this study is that following disaster found be associated small adults. Our findings help identify discussion points planning, including preparedness, response recovery measures, applicable future disasters requiring mass evacuation.
Язык: Английский
Процитировано
90
Journal of Atherosclerosis and Thrombosis, Год журнала: 2024, Номер unknown
Опубликована: Янв. 1, 2024
Aims: Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), when taken as monotherapy in combination with ezetimibe on background of statins, clinical trials predominantly conducted Northern European/Caucasian participants. We characterized the efficacy, safety, tolerability obicetrapib within an Asian-Pacific region population.
Язык: Английский
Процитировано
11
Journal of Advanced Research, Год журнала: 2024, Номер unknown
Опубликована: Март 1, 2024
Atherosclerosis is a chronic and complex disease caused by lipid disorder, inflammation, other factors. It closely related to cardiovascular diseases, the chief cause of death globally. Peroxisome proliferator-activated receptors (PPARs) are valuable anti-atherosclerosis targets that showcase multiple roles at different pathological stages atherosclerosis for cell types tissue sites. Aim Review: Considering spatial temporal characteristics evolution atherosclerosis, pharmacological clinical studies PPARs were summarized systematically updated under in vascular cells atherosclerosis. Moreover, selective PPAR modulators PPAR-pan agonists can exert their synergistic effects meanwhile reducing side effects, thereby providing novel insight into future drug development precise spatial–temporal therapeutic strategy targeting PPARs. Key Scientific Concepts Based on we have proposed importance stage- type-dependent precision therapy. Initially, improve endothelial cells' dysfunction inhibiting inflammation oxidative stress then regulate macrophages' metabolism polarization fatty streak. Finally, reduce fibrous cap formation suppressing proliferation migration smooth muscle (VSMCs). Therefore, research type-specific mechanisms provide foundation space–time treatment. demonstrated several drugs or compounds activation Selective (that specifically activate gene subsets PPARs) cell-specific effects. Furthermore, dual- pan-PPAR agonist could perform better role balancing efficacy cells/tissue-specific basis therapy
Язык: Английский
Процитировано
10
Circulation Journal, Год журнала: 2024, Номер 88(5), С. 763 - 842
Опубликована: Март 12, 2024
8CQ: Is comprehensive risk assessment using prediction models for the primary prevention of CVD helpful in reducing mortality?
Язык: Английский
Процитировано
7
Journal of Atherosclerosis and Thrombosis, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), is a pervasive chronic disease that affects millions of people worldwide. It predisposes individuals to range severe microvascular and macrovascular complications, which drastically impact the patient's quality life increase mortality rates owing various comorbidities. This extensive review explores intricate pathophysiology underlying diabetic focusing on key mechanisms, such as atherosclerosis, insulin resistance, inflammation, endothelial dysfunction. also highlights recent therapeutic advancements, including introduction SGLT2 inhibitors GLP-1 receptor agonists, provide benefits beyond glycemic control offer cardiovascular renal protection. Furthermore, future position agonists in terms prevention diseases will be discussed. Considering differences secretion capacity between Western Asian patients, Japanese we propose treatment strategy for high-quality Japan.
Язык: Английский
Процитировано
1
Circulation Reports, Год журнала: 2025, Номер 7(2), С. 131 - 138
Опубликована: Янв. 10, 2025
Background: Intensive lipid-lowering therapy (ILLT) is crucial for preventing secondary acute coronary syndrome (ACS). However, achieving target low-density lipoprotein cholesterol (LDL-C) levels remains challenging in clinical practice.
Язык: Английский
Процитировано
1
Journal of Cardiovascular Development and Disease, Год журнала: 2025, Номер 12(2), С. 60 - 60
Опубликована: Фев. 5, 2025
Vascular endothelial function plays an important role in the pathogenesis of atherosclerosis. The reduction low-density lipoprotein cholesterol (LDL-C) is a key therapy for preventing coronary artery disease (CAD), but omega-3 fatty acids as residual risk factors CAD remains controversial. We studied correlation between serum acid levels and patients with receiving statin examined effect eicosapentaenoic (EPA) on function. A total 150 consecutive (LDL-C < 100 mg/dL) were enrolled. Serum measured, was assessed by flow-mediated dilation (FMD) brachial artery. Subsequently, 65 impaired FMD (<6%) low EPA/arachidonic (AA) (<0.3) administered EPA, reassessed after 3 months. multivariate linear regression analysis demonstrated that docosahexaenoic (DHA) EPA plus DHA independent determinants %FMD (β = 0.214 0.163, p 0.05, respectively). significantly improved (from 3.7 ± 1.0% to 4.1 1.0%, 0.05) EPA/AA, especially EPA/AA high triglyceride 3.4 4.0 1.1%, 0.01). associated dysfunction therapy. improves those triglycerides.
Язык: Английский
Процитировано
1
Journal of Atherosclerosis and Thrombosis, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Long-term safety and efficacy of pemafibrate once-daily extended-release (XR) tablets, taken in morning or evening, were evaluated dyslipidemic patients with high triglycerides (TG). In this multicenter, randomized, open-label, parallel-group, phase 3 long-term study, TG randomly assigned to evening administration XR for 52 weeks. The dose was started at 0.2 mg/day increased 0.4 having fasting serum ≥ 150mg/dL during treatment. primary endpoint percent change TG. study enrolled 121 patients, assigning 61 60 administration. population included 71.1% males. Mean age 58.5±11.1 (mean±SD) years, body mass index 27.7±4.3 kg/m2, 264.0±109.2 mg/dL. Fasting decreased significantly from baseline weeks among overall the groups (-45.7%, -44.8%, -46.6%, respectively, p＜0.001 vs. baseline). difference least-squares mean between 3.0%, not statistically significant. 82 (44 38 evening), 57.3% (95%CI 45.9, 68.2) achieving ＜150 Adverse events occurred 83.5% adverse drug reactions 19.0% but no notable problems. Long-term, effective safe provided favorable TG-lowering effects regardless administration, increase proved initially inadequate response.
Язык: Английский
Процитировано
1
Journal of Atherosclerosis and Thrombosis, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
We evaluated the efficacy and safety of bempedoic acid, an ATP-citrate lyase inhibitor, at doses 60, 120, 180 mg, administered for 12 weeks in conjunction with ongoing treatments (e.g., statin and/or other lipid-modifying therapy) determined phase 3 trial dosage Japanese patients. This multicenter, randomized, double-blind, placebo-controlled, parallel-group, 2b included patients hypercholesterolemia risk cardiovascular events inadequate response to statins/statin intolerance. The percentage change low-density lipoprotein cholesterol (LDL-C) from baseline week was calculated. acid 60 120 placebo groups 47, 46, 48, 47 patients, respectively; 79% had statins 21% Relative (-1.9%), LDL-C reduction significantly greater treatment (least squares mean: -10.6%; -21.9%; -21.3%; p＜0.01 vs. placebo). Patients intolerance who were treated showed improved levels by 12. incidence treatment-emergent adverse higher acid-treated (60 57.4%; 54.3%; 58.3%) than group (38.3%). There no increasing trend doses. Adverse related muscular hepatic disorders infrequent, new or worsening cases diabetes reported. elevated confirmed. mg found be appropriate a trial.
Язык: Английский
Процитировано
1